Shares of other companies:
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
DVA Stock News and Mentions of DaVita Inc. Stocktwits
Updated: April 27, 2024 (09:14)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where DaVita Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of DaVita Inc. (DVA).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the DaVita stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of DaVita Inc. (DVA)
April 27, 2024 (10:10) / "Motley Fool" (by Keith Speights)
Warren Buffett's 3 Best-Performing Stocks So Far in 2024: Are They Buys Now?
These high-flying Buffett stocks could be attractive to different kinds of investors.
In Article Trend: Bullish
April 26, 2024 (11:00) / "Benzinga" (by Globe Newswire)
Benevity's 2024 Corporate Goodness Awards Celebrate Groundbreakers in Social Impact
PALM SPRINGS, Calif., April 26, 2024 ( GLOBE NEWSWIRE ) -- Benevity Inc., the leading global provider of social impact software, today announced the winners of its 2024 Corporate Goodness Awards, also known as "The Goodies," acknowledging leading-edge brands for their innovative and ...
In Article Trend: Bullish
April 25, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
DaVita HealthCare ( DVA ) Increases Despite Market Slip: Here's What You Need to Know
DaVita HealthCare (DVA) concluded the recent trading session at $132.77, signifying a +0.02% move from its prior day's close.
In Article Trend: Somewhat-Bullish
April 25, 2024 (20:45) / "PR Newswire" (by Inc.)
Mahesh Krishnan Elected to Halozyme's Board of Directors
SAN DIEGO, April 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. ( NASDAQ: HALO ) ( "Halozyme" ) today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
In Article Trend: Somewhat-Bullish
April 24, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Amedisys ( AMED ) Q1 Earnings and Revenues Surpass Estimates
Amedisys (AMED) delivered earnings and revenue surprises of 1.98% and 1.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Somewhat-Bullish
April 23, 2024 (19:32) / "Benzinga" (by Zacks)
Philips' Zenition 30 to Boost Image-Guided Surgeries - Cencora ( NYSE:COR ) , Cardinal Health ( NYSE:CAH )
Koninklijke Philips PHG recently announced the receipt of FDA 510 ( k ) approval for its Zenition 30 mobile C-arm. The approval is likely to make image-guided surgical procedures available to more patients at a lower cost in the United States.
In Article Trend: Somewhat-Bullish
April 23, 2024 (14:44) / "Zacks Commentary" (by Zacks Equity Research)
Philips' ( PHG ) Zenition 30 to Boost Image-Guided Surgeries
Philips (PHG) announces the FDA clearance for its Zenition 30 mobile C-arm, which is intended to aid in image-guided procedures at a relatively affordable cost.
In Article Trend: Somewhat-Bullish
April 23, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Is Trending Stock DaVita Inc. ( DVA ) a Buy Now?
Recently, Zacks.com users have been paying close attention to DaVita HealthCare (DVA). This makes it worthwhile to examine what the stock has in store.
In Article Trend: Somewhat-Bullish
April 22, 2024 (20:22) / "Investors Business Daily" (by Investor's Business Daily)
Nvidia, Tesla Among S&P 500's Biggest Movers Monday
S&P 500 Stocks: Ford, Nvidia Among Top Performers Monday. Tesla Extends Losses Investor's Business Daily ...
In Article Trend: Neutral
April 22, 2024 (14:44) / "Zacks Commentary" (by Zacks Equity Research)
Neogen ( NEOG ) Inks Genomics Deal to Aid in Food Tracing
Neogen (NEOG) announces a genomics relationship with Performance Food Group to trace food products back to their origin using PathProven food trace technology.
In Article Trend: Somewhat-Bullish
April 19, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
DaVita HealthCare ( DVA ) Advances While Market Declines: Some Information for Investors
DaVita HealthCare (DVA) closed at $127.82 in the latest trading session, marking a +1.36% move from the prior day.
In Article Trend: Neutral
April 19, 2024 (15:43) / "Zacks Commentary" (by Zacks Equity Research)
Reasons Why You Should Retain Masimo ( MASI ) Stock for Now
Masimo's (MASI) R&D activities raise optimism about the stock.
In Article Trend: Somewhat-Bullish
April 19, 2024 (15:14) / "Zacks Commentary" (by Zacks Equity Research)
CVRx's ( CVRX ) Latest Data Favors Barostim's Long-Term Benefits
CVRx's (CVRX) announcement of the availability of additional data supporting the long-term benefits of Barostim is likely to lead to improved patient care.
In Article Trend: Somewhat-Bullish
April 19, 2024 (13:55) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare's ( GEHC ) Voluson to Aid Women's Health Imaging
GE HealthCare (GEHC) announces its latest AI-powered Voluson Signature 20 and 18 ultrasound systems, which are likely to provide effective and efficient care for conditions impacting women's health.
In Article Trend: Somewhat-Bullish
April 19, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
AtriCure's ( ATRC ) cryoSPHERE+ Probe to Aid in Pain Management
AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.
In Article Trend: Somewhat-Bullish
April 19, 2024 (11:59) / "Zacks Commentary" (by Zacks Equity Research)
Intuitive Surgical ( ISRG ) Q1 Earnings Beat, Procedures Robust
Intuitive Surgical's (ISRG) first-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.
In Article Trend: Somewhat-Bullish
April 18, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
DaVita HealthCare ( DVA ) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw DaVita HealthCare (DVA) settling at $126.11, representing a -1.2% change from its previous close.
In Article Trend: Neutral
April 18, 2024 (17:36) / "Zacks Commentary" (by Zacks Equity Research)
Outset Medical ( OM ) Inks Multi-Year Deal to Boost Home Dialysis
Outset Medical's (OM) latest agreement is likely to provide patients and caregivers access to innovative home dialysis with the Tablo Hemodialysis System.
In Article Trend: Somewhat-Bullish
April 18, 2024 (16:17) / "Zacks Commentary" (by Zacks Equity Research)
Why You Should Add Inspire Medical ( INSP ) to Your Portfolio
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
In Article Trend: Bullish
April 18, 2024 (15:09) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Medtronic ( MDT ) Stock for Now
Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.
In Article Trend: Somewhat-Bullish
April 18, 2024 (15:07) / "Zacks Commentary" (by Zacks Equity Research)
IceCure Medical ( ICCM ) Submits Final Cryoablation Data to FDA
IceCure Medical (ICCM) submits final ICE data along with multiple sub-analysis to the FDA seeking approval for marketing authorization for treating early-stage breast cancer.
In Article Trend: Neutral
April 18, 2024 (14:33) / "Investors Business Daily" (by ALLISON GATLIN)
Could Eli Lilly's Sleep Apnea News Actually Help This CPAP Maker?
ResMed Stock Reverses Higher As Weight-Loss Drugs Seen Bolstering Its Devices Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 18, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why DaVita HealthCare ( DVA ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
In Article Trend: Somewhat-Bullish
April 18, 2024 (13:30) / "PR Newswire"
Highly Respected Corporate Partners Join Crowell's Chicago Office - PR Newswire
Highly Respected Corporate Partners Join Crowell's Chicago Office PR ...
In Article Trend: Somewhat-Bullish
April 18, 2024 (12:26) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain DexCom ( DXCM ) Stock in Your Portfolio for Now
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
In Article Trend: Somewhat-Bullish
April 17, 2024 (17:00) / "Zacks Commentary" (by Zacks Equity Research)
PacBio ( PACB ) Preliminary Q1 Revenues Dampened by Purchase Delays
PacBio's (PACB) revenue growth in the first quarter is likely to have been hampered by an increasing number of customers delaying instrument purchases and softness in consumable shipments.
In Article Trend: Neutral
April 17, 2024 (15:07) / "Zacks Commentary" (by Zacks Equity Research)
Henry Schein ( HSIC ) Global Presence Aids, Macroeconomic Woes Stay
Henry Schein (HSIC) is busy promoting digital workflows for general dentistry and dental specialties.
In Article Trend: Somewhat-Bullish
April 17, 2024 (14:48) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare ( GEHC ) , RSNA Unite to Aid Breast Cancer Imaging
GE HealthCare (GEHC) and RSNA collaborate to provide radiologists at Muhimbili National Hospital a test mammography technology and advanced imaging training to aid in the treatment of breast cancer.
In Article Trend: Somewhat-Bullish
April 17, 2024 (14:26) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Chemed ( CHE ) Stock for Now
Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.
In Article Trend: Somewhat-Bullish
April 17, 2024 (11:44) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Hold West Pharmaceutical ( WST ) in Your Portfolio Now
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
In Article Trend: Somewhat-Bullish
April 17, 2024 (11:43) / "Zacks Commentary" (by Zacks Equity Research)
Masimo ( MASI ) Gains Nearly 18% YTD: What's Driving the Rally?
Masimo's (MASI) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.
In Article Trend: Somewhat-Bullish
April 16, 2024 (16:30) / "Zacks Commentary" (by Zacks Equity Research)
Revvity's ( RVTY ) Launch to Boost Pharma-Contract Partner Tie-Up
Revvity's (RVTY) latest offering is likely to significantly accelerate the pace of drug innovation, with efficient data sharing into one seamless platform.
In Article Trend: Somewhat-Bullish
April 16, 2024 (14:56) / "Zacks Commentary" (by Zacks Equity Research)
Bio-Rad ( BIO ) Hurt by Softness in BioPharma and Competition
Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.
In Article Trend: Neutral
April 16, 2024 (13:38) / "Zacks Commentary" (by Zacks Equity Research)
Philips ( PHG ) Agrees to a Consent Decree With DOJ and FDA
Philips (PHG) announces a consent decree with the U.S. government and FDA over Respironics' business recalls.
In Article Trend: Somewhat-Bullish
April 16, 2024 (06:14) / "Stocknews.com" (by Defense World Staff)
DaVita ( NYSE:DVA ) Rating Lowered to Buy at StockNews.com
DaVita ( NYSE:DVA - Get Free Report ) was downgraded by stock analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research report issued on Tuesday.
In Article Trend: Somewhat-Bullish
April 15, 2024 (17:18) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare ( GEHC ) to Showcase Enhanced Breast Cancer Imaging
GE HealthCare's (GEHC) latest breast cancer detection technology is likely to enhance the detection and diagnosis of breast cancer and improve patient outcomes.
In Article Trend: Somewhat-Bullish
April 15, 2024 (14:54) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) , MD Revolution Unite to Boost Diabetes Management
DexCom (DXCM) and MD Revolution collaborate to integrate Dexcom's continuous glucose monitoring systems with MD Revolution's remote care management platform to boost remote diabetes management.
In Article Trend: Bullish
April 15, 2024 (12:19) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Glaukos ( GKOS ) Stock for Now
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
In Article Trend: Somewhat-Bullish
April 12, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
DaVita HealthCare ( DVA ) Stock Moves -0.75%: What You Should Know
In the most recent trading session, DaVita HealthCare (DVA) closed at $130.42, indicating a -0.75% shift from the previous trading day.
In Article Trend: Somewhat-Bullish
April 12, 2024 (15:47) / "Zacks Commentary" (by Zacks Equity Research)
QuidelOrtho's ( QDEL ) New Test to Offer Enhanced Opioid Testing
QuidelOrtho's (QDEL) addition of the Fentanyl Test is likely to deliver rapid drugs-of-abuse detection amidst the escalating opioid crisis.
In Article Trend: Neutral
April 12, 2024 (15:04) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Hold BD ( BDX ) Stock in Your Portfolio
BD's (BDX) slew of product launches and strategic deals raises optimism about the stock.
In Article Trend: Somewhat-Bullish
April 12, 2024 (15:00) / "Zacks Commentary" (by Zacks Equity Research)
Baxter's ( BAX ) New Injectables Aid Its Pharmaceutical Portfolio
Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:22) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Hold The Cooper Companies ( COO ) in Your Portfolio Now
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:22) / "Zacks Commentary" (by Zacks Equity Research)
Glaukos ( GKOS ) Gains Nearly 25% YTD: What's Driving the Rally?
Glaukos' (GKOS) shares have risen year to date on the back of strong fundamentals. However, rising costs can be a cause of concern.
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp's ( LH ) At-Home Mpox Testing Kit Gets the FDA's EUA Nod
Labcorp (LH) receives the FDA's Emergency Use Authorization for the Mpox PCR Test Home Collection Kit.
In Article Trend: Neutral
April 12, 2024 (13:03) / "Zacks Commentary" (by Zacks Equity Research)
Why You Should Add Haemonetics ( HAE ) to Your Portfolio Now
Recovery within the Hospital business and the favorable prospects of the Plasma franchise raise investors' optimism for Haemonetics (HAE).
In Article Trend: Somewhat-Bullish
April 11, 2024 (10:30) / "Motley Fool" (by Will Healy)
The Best Warren Buffett Stocks to Buy With $300 Right Now
Even with $300, many Buffett investments are within reach of the average investor.
In Article Trend: Somewhat-Bullish
April 10, 2024 (18:43) / "Zacks Commentary" (by Ethan Feller)
Market Jitters: 2 Top Ranked Stocks for Defensive Positioning
With the jump in inflation and rise in interest rate uncertainty investors may want to consider defensive stocks ...
In Article Trend: Somewhat-Bullish
April 10, 2024 (17:35) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Add DaVita ( DVA ) to Your Portfolio
DaVita's (DVA) strength in its kidney care raises optimism about the stock.
In Article Trend: Somewhat-Bullish
April 10, 2024 (17:31) / "Zacks Commentary" (by Zacks Equity Research)
Integer Holdings ( ITGR ) Hits 52-Week High: What's Driving It?
Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.
In Article Trend: Somewhat-Bullish
April 10, 2024 (15:58) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Hold Baxter International ( BAX ) in Your Portfolio
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, raises optimism.
In Article Trend: Somewhat-Bullish
April 10, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Should Value Investors Buy DaVita ( DVA ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
In Article Trend: Somewhat-Bullish
April 10, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Is Cresco Labs Inc. ( CRLBF ) Stock Outpacing Its Medical Peers This Year?
Here is how Cresco Labs Inc. (CRLBF) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
In Article Trend: Somewhat-Bullish
April 10, 2024 (13:36) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain Fresenius Medical ( FMS ) in Your Portfolio Now
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
In Article Trend: Somewhat-Bullish
April 10, 2024 (13:33) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Merit Medical ( MMSI ) Stock for Now
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
In Article Trend: Bullish
April 10, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Is Most-Watched Stock DaVita Inc. ( DVA ) Worth Betting on Now?
Zacks.com users have recently been watching DaVita HealthCare (DVA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In Article Trend: Somewhat-Bullish
April 9, 2024 (18:13) / "Zacks Commentary" (by Zacks Equity Research)
Elevance Health ( ELV ) Brand Inks Deal to Better Serve Georgia
Elevance Health's (ELV) brand, Anthem Blue Cross and Blue Shield, collaborates to make the benefits of Piedmont's healthcare network available to its members across specific Georgia regions.
In Article Trend: Somewhat-Bullish
April 9, 2024 (15:47) / "Zacks Commentary" (by Zacks Equity Research)
Why You Should Retain Integer Holdings ( ITGR ) Stock for Now
Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.
In Article Trend: Somewhat-Bullish
April 9, 2024 (15:04) / "Zacks Commentary" (by Zacks Equity Research)
Why You Should Retain Inari Medical ( NARI ) Stock for Now
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
In Article Trend: Somewhat-Bullish
April 9, 2024 (14:59) / "Zacks Commentary" (by Zacks Equity Research)
Shockwave Medical's ( SWAV ) Reducer Receives Positive Results
Shockwave Medical (SWAV) announces the 'real-world' results of the REDUCER-I study, which is intended to collect long-term outcomes on Shockwave Reducer, a novel treatment for refractory angina.
In Article Trend: Somewhat-Bullish
April 9, 2024 (14:08) / "Benzinga" (by Zacks)
Philips ( PHG ) Boosts Patient Monitoring With SmartQare Deal - AdaptHealth ( NASDAQ:AHCO ) , Cardinal Health ( NYSE:CAH )
Philips PHG is leaving no stone unturned to bolster its patient monitoring solutions portfolio on the back of recent collaborations. In this regard, the company partnered with smartQare to integrate the latter's viQtor solution into its clinical patient monitoring platforms.
In Article Trend: Bullish
April 9, 2024 (13:03) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp's ( LH ) Strategic Alliances Aid Amid Macroeconomic Woes
Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.
In Article Trend: Somewhat-Bullish
April 9, 2024 (12:41) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain Integra ( IART ) Stock Now
Integra's (IART) strong focus on portfolio optimization and international expansion bolsters investors' confidence in the stock.
In Article Trend: Somewhat-Bullish
April 9, 2024 (12:35) / "Benzinga" (by Globe Newswire)
FullBloom Expands Leadership Team with Key Appointments
PHILADELPHIA, April 09, 2024 ( GLOBE NEWSWIRE ) -- FullBloom, the leading child development services platform for academic, behavioral, and emotional intervention, today announced the expansion of its executive leadership team with the appointments of Akosua Kankam as chief revenue officer ( CRO ...
In Article Trend: Somewhat-Bullish
April 9, 2024 (12:34) / "Zacks Commentary" (by Zacks Equity Research)
Thermo Fisher ( TMO ) Launches TSX Universal Series ULT Freezers
Thermo Fisher's (TMO) new ENERGY STAR-certified TSX Universal Series ULT Freezers deliver tighter temperature control and faster recovery times.
In Article Trend: Somewhat-Bullish
April 9, 2024 (07:56) / "Stocknews.com" (by Defense World Staff)
DaVita ( NYSE:DVA ) Upgraded by StockNews.com to "Strong-Buy"
StockNews.com upgraded shares of DaVita ( NYSE:DVA - Free Report ) from a buy rating to a strong-buy rating in a research report report published on Monday morning. A number of other analysts have also recently weighed in on the stock.
In Article Trend: Somewhat-Bullish
April 8, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Why the Market Dipped But DaVita HealthCare ( DVA ) Gained Today
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $133.73, denoting a +0.09% change from the preceding trading day.
In Article Trend: Somewhat-Bullish
April 8, 2024 (14:41) / "Zacks Commentary" (by Zacks Equity Research)
Glaukos ( GKOS ) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
In Article Trend: Somewhat-Bullish
April 8, 2024 (14:29) / "Zacks Commentary" (by Zacks Equity Research)
Philips ( PHG ) Boosts Patient Monitoring With smartQare Deal
Philips (PHG) partners with smartQare to integrate the latter's viQtor solution, boosting its patient monitoring solutions portfolio.
In Article Trend: Bullish
April 8, 2024 (14:27) / "Zacks Commentary" (by Zacks Equity Research)
BD's ( BDX ) Latest Product to Offer Wider Access to Researchers
The latest worldwide commercial availability of BD's (BDX) cell sorters is set to expand researchers' capabilities to transform research and cell-based therapeutic development across numerous fields.
In Article Trend: Somewhat-Bullish
April 8, 2024 (14:25) / "Zacks Commentary" (by Zacks Equity Research)
Silk Road Medical's ( SILK ) New Launch to Aid Its TCAR Portfolio
Silk Road Medical (SILK) announces its latest launch of ENROUTE Transcarotid Neuroprotection System PLUS, which is likely to aid in TCAR procedures.
In Article Trend: Somewhat-Bullish
April 8, 2024 (14:10) / "Zacks Commentary" (by Zacks Equity Research)
Abbott ( ABT ) Faces Low Testing Demand, Currency Headwinds
Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.
In Article Trend: Somewhat-Bullish
April 8, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
IM Cannabis ( IMCC ) Expands Business in Germany With New Alliance
The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.
In Article Trend: Bullish
April 8, 2024 (12:18) / "Zacks Commentary" (by Zacks Equity Research)
Teleflex ( TFX ) Debuts the New Unified UroLift 2 System With ATC
Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.
In Article Trend: Somewhat-Bullish
April 5, 2024 (16:29) / "Benzinga" (by Zacks)
Diagnosing the Economy Ahead of World Health Day: 6 Picks - Lancaster Colony ( NASDAQ:LANC ) , DaVita ( NYSE:DVA )
After wrapping up a robust first quarter on strong corporate profits, enthusiasm around AI and hopes that the Fed will cut rates, Wall Street's rally fizzled out to start Q2 on uncertainty over the timing of rate cuts.
In Article Trend: Bullish
April 5, 2024 (15:52) / "Zacks Commentary" (by Zacks Equity Research)
AngioDynamics ( ANGO ) Q3 Earnings and Revenues Miss Estimates
Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.
In Article Trend: Neutral
April 5, 2024 (15:43) / "Zacks Commentary" (by Zacks Equity Research)
AngioDynamics' ( ANGO ) AlphaVac Gets FDA Nod for PE Treatment
AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
In Article Trend: Somewhat-Bullish
April 5, 2024 (13:52) / "Zacks Commentary" (by Zacks Equity Research)
Abbott ( ABT ) Receives FDA's Approval for the TriClip TEER System
Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.
In Article Trend: Somewhat-Bullish
April 5, 2024 (12:14) / "Zacks Commentary" (by Sweta Killa)
Diagnosing the Economy Ahead of World Health Day: 6 Picks
Similar to the six vital nutrients required for good health, we have examined the six pillars that support the economy and zeroed in on stocks that have a Zacks Rank #1 (Strong Buy) or 2 (Buy) and a higher market cap in their respective sectors.
In Article Trend: Bullish
April 5, 2024 (11:17) / "Zacks Commentary" (by Zacks Equity Research)
Henry Schein ( HSIC ) Buys TriMed to Expand in Orthopedic Space
According to Henry Schein (HSIC), the upper and lower extremities are among the fastest-growing segments of orthopedics, representing a total addressable market of more than $5.5 billion.
In Article Trend: Somewhat-Bullish
April 5, 2024 (11:00) / "Zacks Commentary" (by Benjamin Rains)
3 Soaring, Highly-Ranked Value Stocks to Buy in April
3 highly-ranked Zacks stocks that offer an attractive combination of impressive valuations, soaring stock prices, and long-term upside in crucial, non-flashy industries.
In Article Trend: Somewhat-Bullish
April 4, 2024 (17:29) / "Benzinga" (by Zacks)
Globus Medical ( GMED ) Gains From New Launches Amid Macro Issues - DaVita ( NYSE:DVA ) , Cardinal Health ( NYSE:CAH )
Globus Medical GMED continues to gain from surging demand for its Musculoskeletal Solutions products. Meanwhile, the company is expanding in the overseas markets through the expansion of direct and distributor sales force.
In Article Trend: Somewhat-Bullish
April 4, 2024 (16:03) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare's ( GEHC ) New Launch to Enhance Cardiac Care
GE HealthCare's (GEHC) latest offering is likely to expand access to cardiac care by enabling more medical professionals to be able to capture cardiac images.
In Article Trend: Somewhat-Bullish
April 4, 2024 (16:02) / "Zacks Commentary" (by Zacks Equity Research)
Glaukos' ( GKOS ) iDose TR Receives Permanent J- Code From CMS
Glaukos (GKOS) announces the receipt of a permanent J-code for iDose TR from the CMS, which is likely to boost the billing and payment process.
In Article Trend: Somewhat-Bullish
April 4, 2024 (15:59) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add Cardinal Health ( CAH ) to Your Portfolio Now
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
In Article Trend: Somewhat-Bullish
April 4, 2024 (14:45) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Add Ecolab ( ECL ) to Your Portfolio Now
Ecolab's (ECL) focus on research and development raises optimism about the stock.
In Article Trend: Somewhat-Bullish
April 4, 2024 (12:41) / "Zacks Commentary" (by Zacks Equity Research)
Globus Medical ( GMED ) Gains From New Launches Amid Macro Issues
Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
In Article Trend: Somewhat-Bullish
April 4, 2024 (12:24) / "Zacks Commentary" (by Zacks Equity Research)
Align ( ALGN ) Debuts Invisalign Palatal Expander in New Markets
Align's (ALGN) Invisalign Palatal Expander system is now available in Australia and New Zealand for skeletal and dental expansion in growing patients.
In Article Trend: Somewhat-Bullish
April 4, 2024 (10:33) / "Motley Fool" (by Matt Frankel)
3 High-Dividend ETFs That Could Be Smart Investments Right Now
These are three great ways to get income in your portfolio without the hard work of choosing stocks and bonds on your own.
In Article Trend: Somewhat-Bullish
April 3, 2024 (21:27) / "Zacks Commentary" (by Zacks Equity Research)
Veeva Systems ( VEEV ) Makes Change to Front Office ( revised )
Veeva Systems' (VEEV) CFO Brent Bowman steps down, leading analysts to weigh in on the impact and prospects for the cloud-solutions company.
In Article Trend: Somewhat-Bullish
April 3, 2024 (14:54) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain PacBio ( PACB ) Stock in Your Portfolio Now
PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.
In Article Trend: Somewhat-Bullish
April 3, 2024 (14:48) / "Zacks Commentary" (by Zacks Equity Research)
QuidelOrtho's ( QDEL ) QuickVue Gets FDA Nod for COVID Testing
QuidelOrtho (QDEL) announces the FDA's approval of QuickVue, which is likely to be used for convenient and accurate COVID-19 pathogen testing.
In Article Trend: Neutral
April 3, 2024 (13:57) / "Zacks Commentary" (by Zacks Equity Research)
Exact Sciences' ( EXAS ) Oncoguard Esophagus Test Looks Promising
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.
In Article Trend: Neutral
April 3, 2024 (13:51) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Buy Alcon ( ALC ) Stock Right Now
Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).
In Article Trend: Somewhat-Bullish
April 3, 2024 (13:30) / "PR Newswire"
Former DaVita IKC General Counsel Stephen Bentfield Joins Crowell & Moring - PR Newswire
Former DaVita IKC General Counsel Stephen Bentfield Joins Crowell & Moring PR ...
In Article Trend: Bullish
April 3, 2024 (13:09) / "Zacks Commentary" (by Zacks Equity Research)
Veeva Systems' ( VEEV ) CFO Resignation Sparks 6% Stock Drop
Veeva Systems' (VEEV) CFO, Brent Bowman, steps down, causing a 6% stock price decline. Analysts weigh in on the impact and prospects for the cloud-solutions company.
In Article Trend: Somewhat-Bullish
April 3, 2024 (13:09) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain CONMED ( CNMD ) Stock for Now
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
In Article Trend: Somewhat-Bullish
April 2, 2024 (16:08) / "Zacks Commentary" (by Zacks Equity Research)
Baxter's ( BAX ) Latest FDA Approval to Boost Infusion Therapy
Baxter's (BAX) Novum IQ Infusion Platform is likely to help enhance patient safety and efficiency for clinicians following the FDA's clearance.
In Article Trend: Somewhat-Bullish
April 2, 2024 (15:18) / "Zacks Commentary" (by Zacks Equity Research)
Three Reasons to Retain Avanos ( AVNS ) Stock in Your Portfolio
Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.
In Article Trend: Somewhat-Bullish
April 2, 2024 (14:32) / "Zacks Commentary" (by Zacks Equity Research)
AngioDynamics ( ANGO ) Settles Patent Litigations With BD
AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.
In Article Trend: Somewhat-Bullish
April 2, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain DENTSPLY SIRONA ( XRAY ) in Your Portfolio Now
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
In Article Trend: Somewhat-Bullish
April 2, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why DaVita HealthCare ( DVA ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
In Article Trend: Bullish
April 2, 2024 (13:06) / "Zacks Commentary" (by Zacks Equity Research)
Prestige Consumer ( PBH ) Banks on its Portfolio Amid Cost Woes
Prestige Consumer (PBH) develops long-term partnerships across its diverse retail footprint and invests heavily in the e-commerce channel.
In Article Trend: Somewhat-Bullish
April 2, 2024 (12:36) / "Zacks Commentary" (by Zacks Equity Research)
Thermo Fisher ( TMO ) Debuts a New In-Line Metrology Solution
Thermo Fisher's (TMO) new LInspector Edge In-line Mass Profilometer delivers real-time, full-coverage mass loading analysis for battery electrode coating.
In Article Trend: Somewhat-Bullish
April 2, 2024 (12:31) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Invest in IDEXX ( IDXX ) Stock Right Now
The strength of the CAG Diagnostics business buoys optimism for IDEXX (IDXX).
In Article Trend: Somewhat-Bullish
April 1, 2024 (17:04) / "Zacks Commentary" (by Zacks Equity Research)
Three Reasons to Retain Revvity ( RVTY ) Stock in Your Portfolio
Revvity's (RVTY) strong product portfolio raises optimism about the stock.
In Article Trend: Somewhat-Bullish
April 1, 2024 (17:01) / "Zacks Commentary" (by Zacks Equity Research)
OPKO Health ( OPK ) to Restructure After Asset Buyout by Labcorp
OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.
In Article Trend: Somewhat-Bullish
April 1, 2024 (14:52) / "Zacks Commentary" (by Zacks Equity Research)
Neuronetics' ( STIM ) FDA-Cleared NeuroStar to Aid in Depression
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
In Article Trend: Somewhat-Bullish
April 1, 2024 (14:41) / "Zacks Commentary" (by Zacks Equity Research)
Tandem Diabetes ( TNDM ) Gains From Innovation Amid Macro Issues
Tandem Diabetes (TNDM) seeks to grow its business through the acquisition of products or technologies and investments in businesses.
In Article Trend: Somewhat-Bullish
April 1, 2024 (14:32) / "Zacks Commentary" (by Zacks Equity Research)
Paragon 28 ( FNA ) Expands Syndesmotic Repair Line With New Launch
The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.
In Article Trend: Somewhat-Bullish
April 1, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add ShockWave Medical ( SWAV ) to Your Portfolio Now
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
In Article Trend: Somewhat-Bullish
April 1, 2024 (12:15) / "Zacks Commentary" (by Zacks Equity Research)
Medtronic's ( MDT ) Newest Evolut TAVR System Gets FDA Approval
Medtronic (MDT) announces the FDA approval of the newest-generation Evolut TAVR system for the treatment of symptomatic severe aortic stenosis.
In Article Trend: Somewhat-Bullish
March 28, 2024 (15:43) / "Zacks Commentary" (by Zacks Equity Research)
McKesson ( MCK ) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
In Article Trend: Somewhat-Bullish
March 28, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Chemed ( CHE ) Up 2.5% Since Last Earnings Report: Can It Continue?
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 28, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare's ( GEHC ) PVA to Aid in Capturing Prostate Volume
GE HealthCare (GEHC) announces the launch of Prostate Volume Assist AI-enabled urology software feature, which is likely to boost prostate imaging, capture prostate volume and increase workflow.
In Article Trend: Bullish
March 28, 2024 (15:26) / "Zacks Commentary" (by Zacks Equity Research)
3 Reasons to Retain Inogen ( INGN ) Stock in Your Portfolio
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.
In Article Trend: Somewhat-Bullish
March 28, 2024 (14:04) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Add Lantheus ( LNTH ) to Your Portfolio
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 28, 2024 (12:03) / "Zacks Commentary" (by Zacks Equity Research)
Boston Scientific ( BSX ) and Scivita Medical Expand Partnership
Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.
In Article Trend: Somewhat-Bullish
March 28, 2024 (12:01) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain Thermo Fisher ( TMO ) Stock
Strength in end markets and strategic collaborations bode well for Thermo Fisher (TMO).
In Article Trend: Somewhat-Bullish
March 27, 2024 (16:29) / "Zacks Commentary" (by Zacks Equity Research)
Accuray's ( ARAY ) CyberKnife Improves Prostate Cancer Treatment
Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.
In Article Trend: Somewhat-Bullish
March 27, 2024 (14:56) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about DexCom's (DXCM) strong product portfolio.
In Article Trend: Somewhat-Bullish
March 27, 2024 (14:54) / "Zacks Commentary" (by Zacks Equity Research)
Stryker's ( SYK ) Latest Launch to Streamline Procedural Workflows
Stryker's (SYK) latest addition to its Gamma legacy is expected to streamline workflows and enhance usability.
In Article Trend: Somewhat-Bullish
March 27, 2024 (11:51) / "Zacks Commentary" (by Zacks Equity Research)
Myriad Genetics ( MYGN ) Wins Foundational Patent for MRD Assay
Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.
In Article Trend: Somewhat-Bullish
March 27, 2024 (11:19) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add Cencora ( COR ) Stock in Your Portfolio Now
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
In Article Trend: Bullish
March 27, 2024 (11:12) / "Zacks Commentary" (by Zacks Equity Research)
Masimo ( MASI ) Plans Consumer Business Spin-Off to Drive Growth
Masimo (MASI) is evaluating a proposed separation of its consumer audio and consumer health product business in a bid to improve the profitability of the healthcare business.
In Article Trend: Somewhat-Bullish
March 26, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Three Reasons to Retain Avantor ( AVTR ) Stock in Your Portfolio
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 26, 2024 (15:26) / "Zacks Commentary" (by Zacks Equity Research)
Veeva Systems' ( VEEV ) Vault EDC Witnesses Increasing Adoption
Veeva Systems' (VEEV) Vault EDC is likely to enable companies to build a modern clinical data foundation.
In Article Trend: Somewhat-Bullish
March 26, 2024 (15:20) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add Veeva Systems ( VEEV ) to Your Portfolio Now
Veeva's strong product demand and strategic deals raise optimism about the stock.
In Article Trend: Somewhat-Bullish
March 26, 2024 (15:17) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare ( GEHC ) to Sell IONIC's FDA-Cleared nCommand Lite
GE HealthCare (GEHC) announces the FDA approval of IONIC Health's nCommand Lite technology, which it will distribute for multi-vendor, multi-modality remote operations purposes exclusively.
In Article Trend: Somewhat-Bullish
March 26, 2024 (14:42) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain Intuitive Surgical ( ISRG ) in Your Portfolio
Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.
In Article Trend: Somewhat-Bullish
March 26, 2024 (13:39) / "Zacks Commentary" (by Zacks Equity Research)
Charles River ( CRL ) Extends Gene Therapy Deal With NUS Medicine
Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.
In Article Trend: Somewhat-Bullish
March 26, 2024 (12:44) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Buy Align Technology ( ALGN ) Stock Now
Investors remain optimistic about Align Technology (ALGN), backed by Invisalign's strong potential and impressive collaborations.
In Article Trend: Somewhat-Bullish
March 25, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Are Investors Undervaluing DaVita ( DVA ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
In Article Trend: Bullish
March 24, 2024 (09:49) / "Motley Fool" (by Keith Speights)
Warren Buffett's Berkshire Hathaway Owns Over 25% of These 4 Companies ( Hint: Apple Isn't One of Them )
Berkshire even lists one of these companies as a subsidiary.
In Article Trend: Somewhat-Bullish
March 22, 2024 (16:24) / "Zacks Commentary" (by Zacks Equity Research)
Tandem Diabetes ( TNDM ) Gains From Innovation Amid Competition
Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.
In Article Trend: Somewhat-Bullish
March 22, 2024 (14:39) / "Zacks Commentary" (by Zacks Equity Research)
Stryker ( SYK ) Acquires SERF SAS to Aid Its Orthopedic Segment
Stryker (SYK) completes its acquisition of SERF SAS, a France-based joint replacement company. With this acquisition, Stryker aims to boost its orthopedic division in the European region.
In Article Trend: Somewhat-Bullish
March 22, 2024 (13:48) / "Zacks Commentary" (by Zacks Equity Research)
Bruker Corporation ( BRKR ) Hits 52-Week High: What's Driving It?
Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.
In Article Trend: Somewhat-Bullish
March 22, 2024 (13:41) / "Zacks Commentary" (by Zacks Equity Research)
Thermo Fisher ( TMO ) Inks Deal to Develop Companion Diagnostics
Thermo Fisher's (TMO) new partnership with Bayer AG is likely to help increase the latter's precision cancer therapies.
In Article Trend: Somewhat-Bullish
March 22, 2024 (13:23) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Hold Patterson Companies ( PDCO ) in Your Portfolio
Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.
In Article Trend: Somewhat-Bullish
March 22, 2024 (13:15) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Hold McKesson ( MCK ) in Your Portfolio
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
In Article Trend: Somewhat-Bullish
March 22, 2024 (12:33) / "Zacks Commentary" (by Zacks Equity Research)
Phibro Stock ( PAHC ) Rises 7% YTD: Will the Run Continue?
Investors are optimistic about Phibro (PAHC), led by the introduction of new products and upbeat guidance.
In Article Trend: Bullish
March 21, 2024 (16:37) / "Zacks Commentary" (by Zacks Equity Research)
Walgreens ( WBA ) to Report Q2 Earnings: What's in the Cards?
Walgreens (WBA) fiscal second-quarter performance is likely to benefit from strong growth in the United States and the International front ...
In Article Trend: Bullish
March 21, 2024 (16:35) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Nevro ( NVRO ) Stock for Now
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 21, 2024 (16:32) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare ( GEHC ) Renews HealthCare Alliance With Hartford
GE HealthCare (GEHC) and Hartford Healthcare announce the renewal of The Care Alliance. The renewal will extend the collaboration through 2030, which started back in 2016.
In Article Trend: Bullish
March 21, 2024 (16:00) / "Zacks Commentary" (by Zacks Equity Research)
DaVita HealthCare ( DVA ) Is Up 1.09% in One Week: What You Should Know
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
In Article Trend: Somewhat-Bullish
March 21, 2024 (14:40) / "Zacks Commentary" (by Zacks Equity Research)
DaVita HealthCare ( DVA ) Is Up 1.09% in One Week: What You Should Know
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
In Article Trend: Somewhat-Bullish
March 21, 2024 (14:05) / "Zacks Commentary" (by Zacks Equity Research)
UnitedHealth ( UNH ) Faces Investigation Following Cyberattack
A cyberattack on UnitedHealth's (UNH) subsidiary, Change Healthcare, last month continues to impact its healthcare services. The HHS investigation will determine any breach of protected health data.
In Article Trend: Neutral
March 21, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add Stryker ( SYK ) Stock in Your Portfolio Now
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
In Article Trend: Bullish
March 21, 2024 (13:39) / "Zacks Commentary" (by Zacks Equity Research)
Revvity's ( RVTY ) New Launch to Boost Research Productivity
Revvity's (RVTY) latest next-generation suite is likely to enhance research productivity and innovation.
In Article Trend: Somewhat-Bullish
March 21, 2024 (12:17) / "Zacks Commentary" (by Vasundhara Sawalka)
4 Stocks Trading Near 52-Week High That Can Climb Further
Investors target stocks that have been on a bullish run lately. Stocks like HST, EAT, DVA and PPC that are seeing price strength have a high chance of carrying the momentum forward.
In Article Trend: Somewhat-Bullish
March 21, 2024 (12:10) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain National Vision ( EYE ) Stock Now
The strong execution of strategic initiatives and robust financial stability bode well for National Vision (EYE).
In Article Trend: Somewhat-Bullish
March 21, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
AdaptHealth Reaches 80-Plus Relative Strength Rating Benchmark
One important metric to look for in a stock is an 80 or higher Relative Strength Rating. AdaptHealth ( AHCO ) cleared that benchmark Thursday, with a jump from 67 to 87 Thursday.
In Article Trend: Bullish
March 20, 2024 (15:29) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Hold Surmodics ( SRDX ) Stock for Now
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
In Article Trend: Somewhat-Bullish
March 20, 2024 (15:28) / "Zacks Commentary" (by Zacks Equity Research)
Merit Medical ( MMSI ) Launches FDA-Cleared Micro-Access System
Merit Medical (MMSI) announces the launch of its latest FDA-approved Micro ACE Advanced Micro-Access System, which is likely to benefit interventional treatments using micro access.
In Article Trend: Somewhat-Bullish
March 20, 2024 (15:26) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Accuray ( ARAY ) Stock for Now
Accuray's (ARAY) solid product demand raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 20, 2024 (13:50) / "Zacks Commentary" (by Zacks Equity Research)
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
In Article Trend: Somewhat-Bullish
March 20, 2024 (11:55) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Buy Phibro ( PAHC ) Stock Now
Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.
In Article Trend: Somewhat-Bullish
March 19, 2024 (17:40) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain Abbott ( ABT ) Stock Now
Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.
In Article Trend: Somewhat-Bullish
March 19, 2024 (17:38) / "Zacks Commentary" (by Zacks Equity Research)
Edwards Lifesciences ( EW ) Up 21.8% YTD: What's Driving It?
Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.
In Article Trend: Bullish
March 19, 2024 (14:51) / "Zacks Commentary" (by Zacks Equity Research)
Johnson & Johnson ( JNJ ) , Nvidia Unite to Boost AI for Surgery
Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.
In Article Trend: Somewhat-Bullish
March 19, 2024 (14:15) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain HealthEquity ( HQY ) Stock Now
HealthEquity's (HQY) strength in HSAs raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 19, 2024 (13:48) / "Zacks Commentary" (by Zacks Equity Research)
Cencora ( COR ) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
In Article Trend: Bullish
March 19, 2024 (12:14) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Tandem Diabetes ( TNDM ) Now
Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).
In Article Trend: Somewhat-Bullish
March 19, 2024 (11:59) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Add Masimo ( MASI ) to Your Portfolio Now
Masimo's (MASI) R&D activities raise optimism about the stock.
In Article Trend: Somewhat-Bullish
March 19, 2024 (10:00) / "CNN" (by Kate Stalter)
How to invest in S&P 500
If you're an investor, or thinking of becoming one, you've almost certainly heard the term "S&P 500," which is often shortened to "S&P." When people ask how "the market" is doing, they're usually referring to the S&P. But even if you already know this popular stock market term, do you know how to ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (09:10) / "Motley Fool" (by CFA)
3 No-Brainer Warren Buffett Stocks to Buy Right Now
Strong brands and market presence make these three companies attractive investments.
In Article Trend: Bullish
March 18, 2024 (16:01) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Inspire Medical ( INSP ) Stock Now
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
In Article Trend: Bullish
March 18, 2024 (15:34) / "Zacks Commentary" (by Zacks Equity Research)
Revvity's ( RVTY ) New Launch to Boost Newborn Sequencing Research
Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.
In Article Trend: Somewhat-Bullish
March 18, 2024 (15:16) / "Zacks Commentary" (by Zacks Equity Research)
Waters ( WAT ) Boosts PFAS Testing Solutions With New Cartridges
Waters (WAT) launches Oasis WAX/GCB and GCB/WAX Cartridges for PFAS testing, thus boosting the Waters Operating segment.
In Article Trend: Somewhat-Bullish
March 18, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
High Tide ( HITI ) Acquires Queen of Bud to Expand Its Portfolio
High Tide (HITI) announces the acquisition of Queen of Bud to boost its in-house cannabis brand portfolio without burdening its significant capital expenditure.
In Article Trend: Bullish
March 18, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
Chemed ( CHE ) Reaches a New 52-Week High: What's Driving It?
Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:29) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain DexCom ( DXCM ) Stock in Your Portfolio for Now
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:28) / "Zacks Commentary" (by Zacks Equity Research)
Boston Scientific ( BSX ) Global Growth Robust, Macro Issues Ail
Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:27) / "Zacks Commentary" (by Zacks Equity Research)
PetIQ ( PETQ ) Broadens Minties Line With Large Dogs Dental Treats
PetIQ (PETQ), with a focus on affordability and natural ingredients, is well-positioned to meet the evolving needs of pet owners and continue its growth trajectory in the pet wellness market.
In Article Trend: Somewhat-Bullish
March 18, 2024 (12:23) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Buy Insulet ( PODD ) Stock Right Now
Investors remain confident in the Insulet (PODD) stock due to the huge success of Omnipod 5.
In Article Trend: Somewhat-Bullish
March 18, 2024 (12:19) / "Zacks Commentary" (by Zacks Equity Research)
Exact Sciences' ( EXAS ) BLUE-C Study Results Published in NEJM
Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.
In Article Trend: Somewhat-Bullish
March 15, 2024 (15:15) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare ( GEHC ) Advances AI Alliance to Improve Workflow
GE HealthCare's (GEHC) evolution of its AI collaboration is likely to lead to digital and AI transformation and provide better patient care and outcomes.
In Article Trend: Bullish
March 15, 2024 (14:50) / "Zacks Commentary" (by Zacks Equity Research)
Edwards Lifesciences ( EW ) Hits 52-Week High: What's Driving It?
Edwards Lifesciences (EW) outperforms the industry, owing to a robust 2023 fourth-quarter performance, as well as the strong potential in the TMTT division.
In Article Trend: Somewhat-Bullish
March 15, 2024 (14:09) / "Zacks Commentary" (by Zacks Equity Research)
Intuitive Surgical's ( ISRG ) Da Vinci 5 Receives FDA Approval
Intuitive Surgical (ISRG) announces the FDA clearance for its next-generation robotic system, da Vinci 5, which is likely to improve surgical workflow and save significant time with better care.
In Article Trend: Somewhat-Bullish
March 15, 2024 (14:04) / "Zacks Commentary" (by Zacks Equity Research)
Waters ( WAT ) Boosts Portfolio Strength With Rheo-IS Accessory
Waters (WAT) unveils Rheo-IS accessory for its TA Instruments Discovery Hybrid Rheometers, bolstering its overall portfolio.
In Article Trend: Somewhat-Bullish
March 15, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
Why DaVita HealthCare ( DVA ) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
In Article Trend: Bullish
March 15, 2024 (13:25) / "Zacks Commentary" (by Zacks Equity Research)
Labcorp ( LH ) Expands Strategic Alliances, Test Sales Fall
Labcorp (LH) continues to progress in terms of integrating hospital partnerships and acquisitions.
In Article Trend: Somewhat-Bullish
March 15, 2024 (12:53) / "Zacks Commentary" (by Zacks Equity Research)
Axonics ( AXNX ) Gets CE Mark for Sacral Neuromodulation System
Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.
In Article Trend: Bullish
March 14, 2024 (16:07) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Hold West Pharmaceutical ( WST ) in Your Portfolio Now
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
In Article Trend: Somewhat-Bullish
March 14, 2024 (15:59) / "Zacks Commentary" (by Zacks Equity Research)
Philips ( PHG ) Expands Sonicare Portfolio With Latest Launch
Philips (PHG) adds Philips One for Kids toothbrush into its Sonicare family, boosting its Personal Health business.
In Article Trend: Bullish
March 14, 2024 (15:57) / "Zacks Commentary" (by Zacks Equity Research)
BD's ( BDX ) ADC System Favored by New Study for Long-Term Care
BD's (BDX) ADC system is likely to result in improvements in clinical workflow, operational efficiency and financial savings in long-term care facilities.
In Article Trend: Bullish
March 14, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
DaVita HealthCare ( DVA ) Up 12% Since Last Earnings Report: Can It Continue?
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Somewhat-Bullish
March 14, 2024 (14:45) / "Zacks Commentary" (by Zacks Equity Research)
Inari Medical's ( NARI ) ClotTriever Improves Patient Outcome
Inari Medical (NARI) announces two-year interim results from the CLOUT registry, which shows a significant improvement in patient's post-thrombotic syndrome and lower rethrombosis-related events.
In Article Trend: Somewhat-Bullish
March 14, 2024 (14:24) / "Zacks Commentary" (by Zacks Equity Research)
Envista ( NVST ) Faces Macroeconomic Challenges, FX Headwind
The challenging macroeconomic conditions are resulting in a significant escalation in Envista's (NVST) costs and expenses.
In Article Trend: Somewhat-Bullish
March 14, 2024 (14:16) / "Zacks Commentary" (by Zacks Equity Research)
Inspira Technologies ( IINN ) Releases Favorable Data on VORTX
Inspira Technologies' (IINN) proprietary orbiting oxygenation technology eliminates the need for membrane fibers, thereby reducing pressure differentials and high shear stress.
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:46) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Charles River ( CRL ) Stock Now
Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:08) / "Zacks Commentary" (by Zacks Equity Research)
New Strong Buy Stocks for March 14th
IMMR, NVR, SKWD, DVA and APAM have been added to the Zacks Rank #1 (Strong Buy) List on March 14, 2024.
In Article Trend: Neutral
March 14, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Chemed's ( CHE ) VITAS Segment Inks New Deal With Covenant Care
Chemed's (CHE) VITAS segment is set to acquire the hospice assets of Covenant Care in Florida and Alabama.
In Article Trend: Bullish
March 14, 2024 (09:39) / "Zacks Commentary" (by Zacks Equity Research)
Best Value Stocks to Buy for March 14th
IMXI, SKWD and DVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 14, 2024.
In Article Trend: Somewhat-Bullish
March 13, 2024 (16:00) / "Zacks Commentary" (by Zacks Equity Research)
AMN Healthcare ( AMN ) Expands Capabilities of ShiftWise Flex
AMN Healthcare's (AMN) expansion of the capabilities of ShiftWise Flex is likely to enhance internal resource pool management for the healthcare system.
In Article Trend: Somewhat-Bullish
March 13, 2024 (14:18) / "Zacks Commentary" (by Zacks Equity Research)
Philips ( PHG ) , AWS Unite to Scale Digital Pathology Solutions
Philips (PHG) collaborates with Amazon Web Services to boost cloud-based pathology solutions. It will enable pathology laboratories to use digital processes to improve analytical capabilities.
In Article Trend: Bullish
March 13, 2024 (14:17) / "Zacks Commentary" (by Zacks Equity Research)
PacBio's ( PACB ) New Panel to Aid Its Clinical Research Solution
PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.
In Article Trend: Somewhat-Bullish
March 13, 2024 (12:34) / "Zacks Commentary" (by Zacks Equity Research)
Alcon's ( ALC ) New Launch Strengthens IOL Innovation Leadership
Alcon's (ALC) Clareon platform is available in India in two PCIOL technologies, PanOptix and Vivity.
In Article Trend: Somewhat-Bullish
March 13, 2024 (11:56) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Glaukos ( GKOS ) Stock for Now
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
In Article Trend: Somewhat-Bullish
March 12, 2024 (15:01) / "Zacks Commentary" (by Zacks Equity Research)
Philips ( PHG ) Aids Personal Health Business With New Campaign
Philips (PHG) launches #ShareTheCare brand positioning campaign for Philips Avent, bolstering the Personal Health segment.
In Article Trend: Bullish
March 12, 2024 (15:01) / "Zacks Commentary" (by Zacks Equity Research)
Orthofix ( OFIX ) Q4 Earnings Beat Estimates, Gross Margin Up
Orthofix's (OFIX) fourth-quarter earnings and revenues beat their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.
In Article Trend: Somewhat-Bullish
March 12, 2024 (14:36) / "Zacks Commentary" (by Zacks Equity Research)
ClearPoint's ( CLPT ) Prism System Favored by Latest Study
ClearPoint's (CLPT) Prism Neuro Laser Therapy System is likely to provide an integrated solution for precise and more efficient laser interstitial thermal therapy.
In Article Trend: Somewhat-Bullish
March 12, 2024 (14:34) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain BD ( BDX ) to Your Portfolio
BD's (BDX) slew of product launches raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 12, 2024 (12:03) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Medtronic ( MDT ) Stock for Now
Investors continue to be optimistic about Medtronic (MDT) on the strength of the Neurosurgery and Cardiovascular and Neurosurgery portfolios.
In Article Trend: Somewhat-Bullish
March 12, 2024 (11:51) / "Zacks Commentary" (by Zacks Equity Research)
Bruker ( BRKR ) Announces Advanced timsTOF Solutions at US HUPO
Bruker (BRKR) advances CCS-Enabled 4D-Proteomics timsTOF solutions for immunopeptidomes and glycoproteomics at the US HUPO 2024.
In Article Trend: Somewhat-Bullish
March 11, 2024 (16:33) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare ( GEHC ) AI Model to Predict Immunotherapy Response
GE HealthCare (GEHC) announces statistics on AI models that collect clinical data to accurately predict the effectiveness and toxicity of cancer immunotherapy.
In Article Trend: Bullish
March 11, 2024 (14:20) / "Zacks Commentary" (by Zacks Equity Research)
Thermo Fisher ( TMO ) Unveils CorEvitas Clinical Registry in GPP
Thermo Fisher's (TMO) new CorEvitas clinical registry addresses an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP.
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:56) / "Zacks Commentary" (by Zacks Equity Research)
Cardinal Health ( CAH ) Hits 52-Week High: What's Driving It?
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:42) / "Zacks Commentary" (by Zacks Equity Research)
Fresenius Medical ( FMS ) Divests Assets to Optimize Portfolio
Fresenius Medical's (FMS) latest asset divestments reflect a milestone in its portfolio optimization program and are likely to improve profitability.
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:18) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Teleflex ( TFX ) Stock for Now
Investors are optimistic about Teleflex (TFX) on robust growth in the Vascular business and strong Urolift prospects.
In Article Trend: Somewhat-Bullish
March 11, 2024 (12:27) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add The Cooper Companies ( COO ) to Your Portfolio Now
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
In Article Trend: Somewhat-Bullish
March 8, 2024 (22:20) / "PR Newswire" (by DaVita)
DaVita Inc. to Participate in the Barclays Global Healthcare Conference 2024
DENVER, March 8, 2024 /PRNewswire/ -- DaVita Inc. ( NYSE: DVA ) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at Barclays Global Healthcare Conference 2024 on ...
In Article Trend: Bullish
March 8, 2024 (16:16) / "Zacks Commentary" (by Zacks Equity Research)
Cigna ( CI ) Unveils Updated Long-Term Growth Targets & Solutions
Cigna (CI) currently estimates long-term average annual adjusted EPS growth within 10-14%. It also came up with new solutions to better manage the rising GLP-1 costs and expand behavioral care.
In Article Trend: Somewhat-Bullish
March 8, 2024 (14:40) / "Zacks Commentary" (by Zacks Equity Research)
Should Value Investors Buy DaVita ( DVA ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
In Article Trend: Bullish
March 8, 2024 (13:21) / "Zacks Commentary" (by Zacks Equity Research)
Integer Holdings ( ITGR ) Hits 52-Week High: What's Aiding It?
Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.
In Article Trend: Somewhat-Bullish
March 8, 2024 (12:57) / "Zacks Commentary" (by Zacks Equity Research)
DexCom's ( DXCM ) Direct-to-Watch Feature to Boost Its G7 System
DexCom (DXCM) announces its direct-to-Apple-Watch feature for the G7 CGM system, which is likely to help people in better management of diabetes monitoring.
In Article Trend: Somewhat-Bullish
March 8, 2024 (12:31) / "Zacks Commentary" (by Zacks Equity Research)
Alcon's ( ALC ) Vivity EDOF IOL Achieves One Million Milestone
Alcon's (ALC) Vivity features the first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.
In Article Trend: Somewhat-Bullish
March 8, 2024 (11:00) / "Zacks Commentary" (by Zacks Investment Research)
Zacks Investment Ideas feature highlights: Apple, Tesla, HCA Healthcare, DaVita and The Progressive
Apple, Tesla, HCA Healthcare, DaVita and The Progressive have been highlighted in this Investment Ideas article.
In Article Trend: Somewhat-Bullish
March 8, 2024 (10:44) / "Zacks Commentary" (by Zacks Equity Research)
Davita ( DVA ) Shares Gain This Week: Will the Rally Continue?
DaVita (DVA) stock soars as Novo Nordisk's study shows that although weight-loss drug reduces death risk for chronic kidney disease patients, demand for dialysis services will remain.
In Article Trend: Neutral
March 8, 2024 (10:41) / "Zacks Commentary" (by Zacks Equity Research)
DexCom ( DXCM ) Soars 10% This Week: What's Fueling the Gain?
A recent approval for DexCom's (DXCM) new CGM device boosts the prospects of the company by broadening the targeted market. Shares gain as investors see strong potential for growth going forward.
In Article Trend: Somewhat-Bullish
March 7, 2024 (17:25) / "Zacks Commentary" (by Ethan Feller)
Market Leaders Rolling Over: Time to Rotate into Defensive Stocks?
Although the stock market has rallied almost nonstop since the start of the year, cracks are beginning to form ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (16:02) / "Zacks Commentary" (by Zacks Equity Research)
Phibro ( PAHC ) Appears Well Poised on Launches, Vaccine Sales
Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.
In Article Trend: Somewhat-Bullish
March 7, 2024 (15:44) / "Zacks Commentary" (by Zacks Equity Research)
QuidelOrtho's ( QDEL ) New Approval to Aid Pre-eclampsia Diagnosis
QuidelOrtho's (QDEL) receipt of Health Canada's approval is likely to aid in the diagnosis of preterm pre-eclampsia and prognosis of delivery in symptomatic women.
In Article Trend: Somewhat-Bullish
March 7, 2024 (15:44) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Retain Inari Medical ( NARI ) in Your Portfolio Now
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.
In Article Trend: Somewhat-Bullish
March 7, 2024 (15:43) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Merit Medical ( MMSI ) Stock for Now
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
In Article Trend: Bullish
March 7, 2024 (12:33) / "Zacks Commentary" (by Zacks Equity Research)
ResMed ( RMD ) Debuts the Smallest Full-Face CPAP Mask AirFit F40
ResMed's (RMD) new AirFit F40 mask combines the ease and comfort of an ultra-compact, full-face mask with the effectiveness of a traditional over-the-nose, full-face mask.
In Article Trend: Somewhat-Bullish
March 7, 2024 (12:29) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Hold on to Neogen ( NEOG ) Stock Now
Solid progress in long-term growth strategies bodes well for Neogen (NEOG).
In Article Trend: Bullish
March 6, 2024 (15:09) / "Zacks Commentary" (by Zacks Equity Research)
DaVita ( DVA ) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about DaVita's (DVA) strength in its kidney care.
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:50) / "Zacks Commentary" (by Zacks Equity Research)
Quanterix ( QTRX ) AD Offering Gets FDA's Breakthrough Device Tag
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:49) / "Zacks Commentary" (by Zacks Equity Research)
DaVita ( DVA ) Expands Operational Footprint Via New Agreement
DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:43) / "Zacks Commentary" (by Zacks Equity Research)
Edwards ( EW ) Gains From RESILIA's Global Adoption, TAVR Growth
With the Critical Care spin-off, Edwards (EW) is looking to pursue growth in TAVR, TMTT and Surgical, as well as new investments in interventional heart failure technologies.
In Article Trend: Somewhat-Bullish
March 6, 2024 (14:15) / "Zacks Commentary" (by Zacks Equity Research)
DaVita Inc. ( DVA ) Hit a 52 Week High, Can the Run Continue?
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
In Article Trend: Somewhat-Bullish
March 6, 2024 (13:46) / "Zacks Commentary" (by Zacks Equity Research)
Stryker ( SYK ) Completes First Arthroplasty Surgery in Europe
Stryker (SYK) completes its first shoulder arthroplasty surgery in Europe using its Blueprint Mixed Reality Guidance system, which aims to benefit shoulder arthroplasty surgeons.
In Article Trend: Somewhat-Bullish
March 6, 2024 (13:45) / "Zacks Commentary" (by Zacks Equity Research)
DexCom's ( DXCM ) Stelo Glucose Biosensor Receives FDA Approval
DexCom's (DXCM) Stelo receives FDA clearance, which makes it the first FDA-approved glucose biosensor to be available over the counter.
In Article Trend: Somewhat-Bullish
March 6, 2024 (11:54) / "Zacks Commentary" (by Zacks Equity Research)
Haemonetics ( HAE ) Signs Agreement to Acquire Attune Medical
Haemonetics' (HAE) acquisition of the privately held Attune Medical is likely to add the pioneering ensoETM device to its EP portfolio.
In Article Trend: Somewhat-Bullish
March 6, 2024 (08:00) / "Investors Business Daily" (by INVESTOR'S BUSINESS DAILY)
DaVita Shows Market Leadership With Jump To 93 RS Rating
DaVita ( DVA ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, with an upgrade from 88 to 93. X This exclusive rating from Investor's Business Daily tracks share price action with a 1 ( worst ) to 99 ( best ) score.
In Article Trend: Bullish
March 5, 2024 (20:21) / "Benzinga" (by Vandana Singh)
Why Are Dialysis Provider Stocks Trading Higher On Tuesday? - Fresenius Medical Care ( NYSE:FMS ) , DaVita ( NYSE:DVA )
Tuesday, Novo Nordisk A/S NVO released the headline results from the kidney outcomes trial, FLOW. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression as well as cardiovascular and kidney death of 24% for people ...
In Article Trend: Neutral
March 5, 2024 (15:56) / "Benzinga" (by Avi Kapoor)
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday - Dave ( NASDAQ:DAVE ) , NIO ( NYSE:NIO ) , Riskified ( NYSE:RSKD )
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. Shares of NIO Inc. NIO rose during Tuesday's session following upbeat quarterly results. NIO reported fourth-quarter revenue of 17.10 billion yuan ( $2.41 billion ) , up by 6.5% year-over-year and down by ...
In Article Trend: Somewhat-Bullish
March 5, 2024 (15:40) / "Investors Business Daily" (by ALLISON GATLIN)
Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News
DaVita Stock Soars As Weight-Loss Drug Looks Unlikely To Undermine Dialysis Investor's Business Daily ...
In Article Trend: Neutral
March 5, 2024 (15:34) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Add Ecolab ( ECL ) to Your Portfolio
Ecolab's (ECL) focus on R&D raises optimism about the stock.
In Article Trend: Somewhat-Bullish
March 5, 2024 (15:15) / "Zacks Commentary" (by Zacks Equity Research)
Lantheus' ( LNTH ) DEFINITY Approved by FDA for Pediatric Use
Lantheus' (LNTH) receipt of the expanded indication for DEFINITY is likely to address unmet medical needs of pediatric patients.
In Article Trend: Somewhat-Bullish
March 5, 2024 (14:49) / "Zacks Commentary" (by Zacks Equity Research)
Penumbra ( PEN ) Gains From Innovation, Mounting Costs Ail
Penumbra (PEN) expects to materially increase both revenues and profitability in the company's international business in the next three years and beyond.
In Article Trend: Somewhat-Bullish
March 5, 2024 (14:00) / "Canada Newswire" (by DaVita Inc.)
DaVita enters into agreement to expand operations in Brazil and Colombia, enter Chile and Ecuador
Expansion would make DaVita the largest dialysis services provider in Latin America DENVER, March 5, 2024 /CNW/ -- DaVita Inc ( NYSE: DVA ) , a leading provider of kidney care services, today announced that it has agreed to terms on the expansion of its international operations in Brazil and ...
In Article Trend: Somewhat-Bullish
March 5, 2024 (13:23) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain Bruker ( BRKR ) Stock Now
The strength of the BSI BioSpin and CALID groups bodes well for Bruker (BRKR).
In Article Trend: Somewhat-Bullish
March 5, 2024 (13:20) / "Zacks Commentary" (by Zacks Equity Research)
What's in the Offing for Brainsway ( BWAY ) in Q4 Earnings?
Brainsway's (BWAY) fourth-quarter 2023 performance is likely to have been impacted by the strong momentum across the entire business.
In Article Trend: Somewhat-Bullish
March 5, 2024 (13:20) / "MarketWatch" (by Ciara Linnane)
Novo Nordisk says Ozempic helped patients with Type 2 diabetes in one new way
The company is planning to file for regulatory approval of a label expansion for Ozempic in the U.S. and European Union in 2024.
In Article Trend: Neutral
March 5, 2024 (12:32) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain CONMED ( CNMD ) Stock for Now
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
In Article Trend: Somewhat-Bullish
March 4, 2024 (16:27) / "Zacks Commentary" (by Zacks Equity Research)
Boston Scientific ( BSX ) Grows IC Business With New FDA Nod
The AGENT DCB of Boston Scientific (BSX) is already available in Europe, parts of Asia Pacific and Latin America.
In Article Trend: Somewhat-Bullish
March 4, 2024 (16:26) / "Zacks Commentary" (by Zacks Equity Research)
ICON ( ICLR ) Gains From Strategic Deals, New Innovations
ICON (ICLR) continues to evolve its collaboration and delivery models, invest in technology, and enhance its project and program management capabilities.
In Article Trend: Bullish
March 4, 2024 (16:23) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add ShockWave Medical ( SWAV ) to Your Portfolio Now
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
In Article Trend: Somewhat-Bullish
March 4, 2024 (13:39) / "Zacks Commentary" (by Zacks Equity Research)
QIAGEN ( QGEN ) Launches AI-Driven Biomedical Knowledge Base
QIAGEN (QGEN) introduces a Biomedical KB-AI knowledge base to accelerate data-driven drug discovery.
In Article Trend: Somewhat-Bullish
March 4, 2024 (13:25) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare's ( GEHC ) New Launch to Enhance Precision Care
GE HealthCare's (GEHC) latest innovations are likely to provide patient-centered care for a broad patient population in a variety of clinical settings.
In Article Trend: Bullish
March 2, 2024 (11:30) / "Forbes" (by John Dobosz)
Berkshire Hathaway Has $168 Billion In Cash: These Stocks Should Be On Buffett's Buy List
Based on what Warren Buffett says and what he owns, it would not be surprising to see Berkshire buy stakes in these 13 stocks.
In Article Trend: Somewhat-Bullish
March 1, 2024 (16:05) / "Zacks Commentary" (by Zacks Equity Research)
Philips ( PHG ) Aids Diagnostic Imaging With Philips CT 5300
Philips (PHG) introduces AI-enabled Philips CT 5300 X-ray CT system, expanding its diagnostic imaging portfolio.
In Article Trend: Bullish
March 1, 2024 (14:36) / "Zacks Commentary" (by Zacks Equity Research)
Quest Diagnostics ( DGX ) Hurt by Lower Testing Sales, Competition
Quest Diagnostics (DGX) faces intense competition, primarily from LabCorp as well as other commercial laboratories and hospitals.
In Article Trend: Somewhat-Bullish
March 1, 2024 (13:43) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Omnicell ( OMCL ) Stock Now
Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.
In Article Trend: Somewhat-Bullish
March 1, 2024 (13:39) / "Zacks Commentary" (by Zacks Equity Research)
Bruker ( BRKR ) Inks Definitive Agreement to Acquire ELITechGroup
Bruker (BRKR) announces a share purchase agreement to acquire the molecular diagnostics innovator ELITechGroup.
In Article Trend: Somewhat-Bullish
March 1, 2024 (12:56) / "Zacks Commentary" (by Urmimala Biswas)
5 Best PEG-Based GARP Stocks for Investors
Here are the five stocks that qualify our screening criteria ??? RCL, DVA, F, FIS and ITRI.
In Article Trend: Somewhat-Bullish
February 29, 2024 (15:11) / "Zacks Commentary" (by Zacks Equity Research)
Waters ( WAT ) Boosts LC Solutions Portfolio With New Software
Waters (WAT) unveils HPLC CONNECT software, bolstering its liquid chromatography solutions portfolio.
In Article Trend: Somewhat-Bullish
February 29, 2024 (15:02) / "Benzinga" (by Benzinga Insights)
Javier Rodriguez Implements A Sell Strategy: Offloads $43.36M In DaVita Stock - DaVita ( NYSE:DVA )
Javier Rodriguez, Chief Executive Officer at DaVita DVA, disclosed an insider sell on February 28, according to a recent SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Rodriguez sold 345,142 shares of DaVita.
In Article Trend: Somewhat-Bullish
February 28, 2024 (14:40) / "Zacks Commentary" (by Zacks Equity Research)
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
In Article Trend: Bullish
February 27, 2024 (16:09) / "Zacks Commentary" (by Zacks Equity Research)
McKesson ( MCK ) Hits 52-Week High: What's Driving the Stock?
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
In Article Trend: Somewhat-Bullish
February 27, 2024 (15:40) / "Zacks Commentary" (by Zacks Equity Research)
Alcon ( ALC ) Faces Rising Expenses, Tough Competitive Scenario
In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.
In Article Trend: Somewhat-Bullish
February 27, 2024 (15:03) / "Zacks Commentary" (by Zacks Equity Research)
Quanterix ( QTRX ) Expands in Alzheimer's Testing With Alliances
Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website